SynthesisFrontiers in nutrition2026
Resveratrol in diabetes and pancreatic function: implications for the exocrine-endocrine pancreatic axis-a systematic review.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic dysfunction plays an important role in the development and progression of diabetes mellitus. Resveratrol, a naturally occurring polyphenolic compound, has attracted considerable interest due to its antioxidant, anti-inflammatory, and metabolic regulatory properties. The aim of this systematic review was to synthesize available evidence regarding the metabolic and pancreatic effects of resveratrol in diabetes mellitus. A systematic literature search of the PubMed/MEDLINE database (2011-2025) identified preclinical studies, randomized controlled trials, systematic reviews, and meta-analyses investigating resveratrol in diabetic contexts. Evidence from experimental and clinical studies indicates that resveratrol may improve glycemic control, attenuate inflammatory responses, reduce oxidative stress, and protect pancreatic β-cell function, primarily through activation of signaling pathways such as sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK). Most available evidence originates from studies in type 2 diabetes mellitus or experimental models of diabetes. Nevertheless, several mechanisms identified in these studies-including modulation of oxidative stress, inflammation, and pancreatic tissue remodeling-may also be relevant to diseases characterized by combined exocrine and endocrine pancreatic dysfunction. In this context, resveratrol may influence biological processes related to the exocrine-endocrine pancreatic axis, including pancreatic inflammation, fibrosis, and β-cell preservation. Overall, current evidence supports the metabolic and pancreatic protective effects of resveratrol in diabetes. However, direct studies investigating its role in pancreatogenic diabetes remain scarce. Future research specifically targeting pancreatic diseases associated with diabetes is needed to clarify the therapeutic potential of resveratrol in disorders affecting the exocrine-endocrine pancreatic axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.